ADVANCING TREATMENTS
WHERE PATIENTS NEED THEM MOST
TREATMENT-RESISTANT DEPRESSION
Depression affects hundreds of millions of people worldwide, yet a substantial proportion do not respond to standard treatments. Neurentis is advancing Quivara™, a late-stage transdermal patch into a Phase III clinical trial specifically for patients with treatment-resistant depression, supported by an established collaboration with Viatris Inc., a global pharmaceutical company.
RARE NEUROLOGICAL
DISEASES
Our pipeline extends into orphan neurodegenerative conditions where patients currently have no approved treatment options. We are developing therapies for progressive supranuclear palsy, multiple system atrophy, and Perry syndrome, all of which carry the potential for orphan drug designation and the regulatory protections that accompany it.
A DIVERSIFIED
PIPELINE
Neurentis is not a single-product company. Our portfolio spans late-stage clinical development, orphan drug candidates, a proprietary natural formulation for mild depression and anxiety, and an artificial intelligence-driven drug discovery programme. This balanced approach is designed to deliver multiple potential value-creation milestones for shareholders.
The Market Opportunity in Neuroscience and Rare Disease
The global neuroscience pharmaceuticals market continues to grow, driven by ageing populations, rising awareness of neurological conditions, and sustained demand for more effective treatments. Within this market, two segments are particularly relevant to Neurentis.
Treatment-resistant depression represents a significant proportion of the broader depression market, with millions of patients worldwide who do not respond adequately to conventional antidepressant therapies. The only significant recent innovation in this space, esketamine (marketed as Spravato® by Johnson and Johnson), has achieved annual sales exceeding $1.5 billion, demonstrating the commercial potential for differentiated treatments.
The orphan drug market, which addresses rare diseases affecting small patient populations, has grown substantially in recent years. Orphan drug designation provides important regulatory incentives, including extended periods of market exclusivity and reduced development fees. The rare neurological conditions that Neurentis is targeting, including progressive supranuclear palsy and multiple system atrophy, currently have no approved disease-modifying treatments, representing a clear and defined unmet need.
Our Approach to Drug Development
Neurentis follows a disciplined "buy and build" strategy, identifying clinically validated or near-clinical-stage assets and advancing them to defined development milestones. By focusing on compounds with established pharmacological profiles and supportive clinical data, we aim to reduce the scientific and regulatory risk that has historically characterised neuroscience drug development.
Our Business Model
Our operating model is deliberately asset-light. Rather than maintaining internal laboratory facilities, we work with specialist contract research organisations to conduct our clinical programmes. This approach allows us to deploy capital directly into clinical development rather than infrastructure, while drawing on the deep pharmaceutical industry experience of our leadership team to design and oversee each programme.
Experienced Team
Neurentis is led by pharmaceutical industry executives each with more than 30 years experience in drug development, licensing, and commercial transactions at major pharmaceutical companies including GlaxoSmithKline, Bristol-Myers Squibb, and Novartis. Our team understands how to identify, develop, and commercialise pharmaceutical assets, and our board directors have complementary expertise across science, medicine, and public capital markets.
Breakthrough solutions to massive problems
Despite existing treatments, many people with mental conditions continue to struggle, making the need for new, effective and safer options crucial. The development of novel treatments for psychiatric disorders can help to improve the quality of life for sufferers and their families by offering a solution that can effectively manage the symptoms of these conditions.
Experienced team & advisors
Our leadership team brings decades of experience from senior roles at global pharmaceutical companies. The Board comprises executive and non-executive directors with deep expertise in drug development, regulatory strategy, pharmaceutical licensing, and the public capital markets. The team is further supported by specialist advisors and organisations with complementary knowledge across science, medicine, and commercial strategy.
A Large & Growing market
The global pharmaceutical market for neuroscience and rare disease treatments is substantial and continues to grow. Healthcare systems worldwide face rising demand for effective therapies in areas where current treatments are either insufficient or entirely absent. The orphan drug segment in particular has demonstrated strong commercial dynamics, with supportive regulatory frameworks, premium pricing structures, and a well-established pattern of larger pharmaceutical companies acquiring or licensing assets from specialist developers. Neurentis is positioned to participate in both the broader depression market and the orphan neurology segment, providing exposure to multiple market opportunities within a single portfolio.
